Pharmacologic Therapy In Traumatic Brain Injury: Update On Experimental Treatment Strategies

Authors: Laurer, H.L.; McIntosh, T.K.

Source: Current Pharmaceutical Design, Volume 7, Number 15, 1 October 2001 , pp. 1505-1516(12)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Considerable effort has led to an increased interest in emerging preclinical and clinical data regarding the pathophysiological changes in the posttraumatic brain. It is widely believed that delayed cell damage and death contributes to behavioral impairment following traumatic brain injury. However, no drug therapy to attenuate this process is available at present, and the development of new therapeutic regimen is urgently warranted. This manuscript represents a compendium of recent preclinical work undertaken to evaluate new pharmacologic strategies in the experimental setting as a first step towards the development of a therapeutic armamentarium directed to improve functional recovery in head-injured patients.

Keywords: Pharmacology therapy; Traumatic brain injury; Cation homeostasis; Glutamate antagonists; Calpain antagonists; Cytoskeleton; Nitric oxide; Nitric oxide synthetase; Free rasical scavengers; Lipid peroxidation

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397285

Publication date: 2001-10-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.